Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2008 2
2009 4
2010 11
2011 6
2012 12
2013 11
2014 14
2015 11
2016 9
2017 8
2018 8
2019 5
2020 6
2021 7
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R; Swiss Group for Clinical Cancer Research (SAKK). Afferi L, et al. Among authors: spahn m. BJU Int. 2024 Mar 8. doi: 10.1111/bju.16318. Online ahead of print. BJU Int. 2024. PMID: 38456541
Stromal-epithelial interaction induces GALNT14 in prostate carcinoma cells.
Czyrnik ED, Wiesehöfer M, Dankert JT, Wach S, Wagner M, Spahn M, Kruithof de Julio M, Wennemuth G. Czyrnik ED, et al. Among authors: spahn m. Front Oncol. 2023 Aug 21;13:1212585. doi: 10.3389/fonc.2023.1212585. eCollection 2023. Front Oncol. 2023. PMID: 37671061 Free PMC article.
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Cathomas R, et al. Among authors: spahn m. J Clin Oncol. 2023 Nov 20;41(33):5131-5139. doi: 10.1200/JCO.23.00363. Epub 2023 Aug 17. J Clin Oncol. 2023. PMID: 37590894 Clinical Trial.
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R. Petrausch U, et al. Among authors: spahn m. BMJ Open. 2023 Jun 7;13(6):e067634. doi: 10.1136/bmjopen-2022-067634. BMJ Open. 2023. PMID: 37286312 Free PMC article.
ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
Schmidt-Hegemann NS, Zamboglou C, Mason M, Mottet N, Hinnen K, De Meerleer G, Cozzarini C, Maingon P, Henry A, Spahn M, Cornford P, Belka C, Wiegel T. Schmidt-Hegemann NS, et al. Among authors: spahn m. Radiother Oncol. 2023 Jun;183:109544. doi: 10.1016/j.radonc.2023.109544. Epub 2023 Feb 20. Radiother Oncol. 2023. PMID: 36813168
Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort.
Marra G, Oderda M, Calleris G, Marquis A, Peretti F, Zitella A, Moschini M, Sanchez-Salas R, Karnes RJ, Kneitz B, Spahn M, Pacchioni D, Gontero P. Marra G, et al. Among authors: spahn m. Transl Androl Urol. 2022 Sep;11(9):1271-1281. doi: 10.21037/tau-21-628. Transl Androl Urol. 2022. PMID: 36217395 Free PMC article.
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.
Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Impellizzieri D, Di Rito L, Zoni E, Mosole S, Elia AR, Rinaldi A, Pereira Mestre R, D'Antonio E, Ferrari M, Stoffel F, Jermini F, Gillessen S, Bubendorf L, Schraml P, Calcinotto A, Corey E, Moch H, Spahn M, Thalmann G, Kruithof-de Julio M, Rubin MA, Theurillat JP. Bolis M, et al. Among authors: spahn m. Nat Commun. 2021 Dec 2;12(1):7033. doi: 10.1038/s41467-021-26840-5. Nat Commun. 2021. PMID: 34857732 Free PMC article.
Swiss germ-cell cancer consensus recommendations.
Beyer J, Berthold D, Bode PK, Cathomas R, Fankhauser CD, Fischer S, Gillessen S, Gross T, Hermanns T, Honecker F, Lorch A, Omlin A, Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M, Stenner F, Bührer E. Beyer J, et al. Among authors: spahn m. Swiss Med Wkly. 2021 Aug 23;151(33-34). doi: 10.4414/SMW.2021.w30023. Swiss Med Wkly. 2021. PMID: 34495606 Free article. Review.
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer.
Eckhardt C, Sbiera I, Krebs M, Sbiera S, Spahn M, Kneitz B, Joniau S, Fassnacht M, Kübler H, Weigand I, Kroiss M. Eckhardt C, et al. Among authors: spahn m. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):484-490. doi: 10.1038/s41391-021-00431-3. Epub 2021 Jul 29. Prostate Cancer Prostatic Dis. 2022. PMID: 34326474 Free PMC article.
100 results